NCCN Guidelines Update Bolsters CNSide’s Role in Leptomeningeal Metastases Monitoring
Event summary
- NCCN updated CNS cancer guidelines, reinforcing CSF analysis as standard for leptomeningeal metastases diagnosis.
- CNSide’s Tumor Cell Enumeration assay demonstrated >2x sensitivity vs. conventional cytology in FORESEE study.
- Plus Therapeutics targets 150M covered lives and 1,250 CNSide tests by year-end 2026.
- Company to rebrand as Cerenome Inc. (NASDAQ: CNSY) effective August 3, 2026.
The big picture
The NCCN guideline update validates CSF-based diagnostics like CNSide, aligning with broader trends toward precision oncology tools that reduce healthcare costs while improving patient outcomes. Plus Therapeutics’ focus on integrating tumor-cell analysis with molecular characterization positions it in an emerging niche of comprehensive CNS cancer monitoring solutions.
What we're watching
- Diagnostic Adoption
- Whether CNSide can sustain its sensitivity advantage in broader clinical adoption beyond leptomeningeal metastases.
- Payer Expansion
- The pace at which Plus Therapeutics achieves its 150M covered lives target amid competitive diagnostic landscape.
- Rebranding Impact
- How the transition to Cerenome Inc. affects investor perception and commercial momentum for CNSide.
Related topics